Vitrafy Life Sciences (VFY) H1 2026 earnings summary

Executive summary

• Achieved a major commercial milestone with a 12-month exclusive agreement with IMV Technologies for animal reproduction, generating immediate and milestone-based revenue and validating the commercialization strategy.

• Expanded US operations with a new office and manufacturing capability in California, new hires, and the launch of the Guardian device, supporting commercial scaling and in-person demos.

• Progressed human health market development, including ongoing collaborations with the US Army Institute of Surgical Research, completion of Phase 1 blood platelet trials, and preparations for cell and gene therapy conferences.

• Completed first release of second-generation Guardian device and software, with FDA registration process underway.

• No significant changes in the state of affairs or material commitments during the period.

Financial highlights

• Revenue for the half-year was $8,868, with total income of $1,984,410, mainly from government grants and R&D incentives.

• Net loss after tax was $7,124,467, a significant improvement from $25,683,508 in the prior period.

• Cash and liquid assets totaled $22.8 million at period end, including $10.1 million in term deposits.

• Immediate revenue from the IMV contract expected to be up to AUD 900,000 over 12 months, plus additional grant funding.

• Loss per share improved to (11.16) cents from (98.64) cents year-over-year.

Outlook and guidance

• Anticipates significant value creation from upcoming milestones: phase II US Army study readouts, FDA registration, and commercial scaling in the US.

• Confident in cash runway through calendar year 2027, even with increased investment in manufacturing and commercialization.

• Focused on expanding and converting customer pipeline opportunities in human health and animal reproduction, with ongoing investment in device supply and scalable manufacturing.

• Continued focus on customer onboarding, education, and success programs to drive recurring revenue.

• Expects completion of FDA Class II medical device clearance in 1H FY2027 to expand commercial opportunities.